Study of effect of oral itraconazole with 2% sertaconazole cream versus oral terbinafine with 2% sertaconazole cream in dermatophytosis
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20232542Keywords:
Tinea, Itraconazole, Terbinafine, Sertaconazole, Efficacy, DermatophytosisAbstract
Background: Dermatophytosis is a common dermatological problem. Recent studies have reported an increase in the prevalence of the disease. Management of dermatophytosis thus has become challenging for both dermatologists and patients due to their resistance to treatment and their refractory nature. Currently the management of dermatophytic infection includes both oral and topical antifungals. The study compared the clinical efficacy and adverse effect profile of systemic with topical drugs.
Methods: Patients were randomly divided into two groups of 90 each. They were given oral Itraconazole 100 mg twice daily with Sertaconazole 2 % cream twice daily (Group A) and oral Terbinafine 250 mg once daily with Sertaconazole 2 % cream twice daily (Group B) till complete resolution of lesions or a maximum of six weeks. The response was assessed by the improvement in signs and symptoms of each of the clinical parameter, pruritus, erythema, scaling.
Results: At week 6, mycological cure was seen in 92.9% in Group A as compared to 86.9% of patients in Group B. There was a significant improvement in percentage change in pruritus, erythema, and scaling in both the groups from 0 to 6 weeks (p-value: <0.0001). Mild adverse effects such as gastrointestinal upset, headache, and raised transaminases were observed which were comparable in both the groups.
Conclusions: On comparison of the groups, we observed that both were effective but Itraconazole with Sertaconazole 2% cream was more efficacious in terms of both clinical (pruritus, scaling, and erythema) and mycological cure.
References
Basak P. Mallick B. Pattanaik S. Prevalence of dermatophytic infections including antifungal susceptibility pattern of dermatophytes in a tertiary care hospital. Int J Res Med Sci. 2019;7:699-705.
Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. Indian Dermatol J. 2016;7:77-86.
Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev. 1995;8:240-59.
Elewski B. Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol. 1993;28:28-34.
Pfaller MA, Sutton DA. Review of in vitro activity of sertaconazole nitrate in the treatment of superficial fungal infections. Diagn Microbiol Infect Dis. 2006;56:147-52.
Agut J, Palacı´n C, Sacrista´n A, Ortiz JA. Inhibition of ergosterol synthesis by sertaconazole in Candida albicans. Arzneimittel-forschung. 1992;42:718-20.
Croxtall JD, Plosker GL. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69:339-59.
Liebel F, Lyte P, Garay M, Babad J, Southall MD. Anti inflammatory and anti itch activity of sertaconazole nitrate. Arch Dermatol Res. 2006;298: 191 9.
Carrillo Munoz AJ, Fernandez Torres B, Cárdenes DC, Guarro J. In vitro activity of sertaconazole against dermatophyte isolates with reduced fluconazole susceptibility. Chemotherapy. 2003;49:248 51.
Shakya NB, Jha MS, Dangol A, Shakya S, Shah A. Efficacy of itraconazole versus terbinafine for the treatment of tinea cruris. Med J Shree Birendra Hosp. 2012;11:24‑6.
Chow KW, Ting HC, Yap YP, Yee KC, Purushotaman A, Subramanian S, et al. Short treatment schedules of itraconazole in dermatophytosis. Int J Dermatol. 1998; 37:446-8.
Ardeshna KP, Rohatgi S, Jerajani HR. Successful treatment of recurrent dermatophytosis with isotretinoin and itraconazole. Indian J Dermatol Venereol Leprol. 2016;82:579‑82.
Donckar PD, Pande S, Richarz U, Gerodia N. Itraconazole: What clinicians should know. Indian J Drugs Dermatol. 2017;3:4‑10.
Elewski B. Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol. 1993;28:28-34.
Poojary SA. Topical antifungals: A review and their role in current management of dermatophytoses. Clin Dermatol Rev. 2017;1:S24-9.
Osborne CS, Leitner I, Favre B, Ryder NS. Amino acid substitution in Trichophyton rubrum squalene epoxidase associated with resistance to terbinafine. Antimicrob Agents Chemother. 2005;49:2840‑4.
Majid I, Sheikh G, Kanth F, Hakak R. Relapse after oral terbinafine therapy in dermatophytosis: A Clinical and mycological study. Indian J Dermatol. 2016;61: 529‑33.
Gaurav V, Bhattacharya SN, Sharma N, Datt S, Kumar P, Rai G, et al. Terbinafine resistance in dermatophytes: Time to revisit alternate antifungal therapy. J Mycol Med. 2021;31:101087.
Dabas Y, Xess I, Singh G, Pandey M, Meena S. Molecular identification and antifungal susceptibility patterns of clinical dermatophytes following CLSI and EUCAST guidelines. J Fungi. 2017;3:17.
Martinez-Rossi NM, Peres NT, Rossi A. Antifungal resistance mechanisms in dermatophytes. Mycopathologia. 2008;166:369-83.
Verma SB, Panda S, Nenoff P, Singal A, Rudramurthy SM, Uhrlass S, et al. The unprecedented epidemic-like scenario of dermatophytosis in India: III. Antifungal resistance and treatment options. Indian J Dermatol Venereol Leprol. 2021;87:468-82.
Kontoyiannis DP, Lewis RE. Toward more effective antifungal therapy: The prospects of combination therapy. Br J Haematol. 2004;126:165-75.
Power calculator for binary outcome equivalence trial. Available at: https://www.sealedenvelope.com/ power/binary-equivalence/. Accessed on 20 February 2023.
Dabas Y, Xess I, Singh G, Pandey M, Meena S. Molecular identification and antifungal susceptibility patterns of clinical dermatophytes following CLSI and EUCAST guidelines. J Fungi. 2017;3:17.
Pai V, Ganavalli A, Kikkeri NN. Antifungal Resistance in Dermatology. Indian J Dermatol. 2018;63:361-8.
Singh SK, Subba N, Tilak R. Efficacy of Terbinafine and Itraconazole in Different Doses and in Combination in the Treatment of Tinea Infection: A Randomized Controlled Parallel Group Open Labeled Trial with Clinico-Mycological Correlation. Indian J Dermatol. 2020;65:284-9.
Baveja S, Vashisht D, Kothari R, Venugopal R, Joshi RK. Comparative evaluation of the efficacy of itraconazole with terbinafine cream versus itraconazole with sertaconazole cream in dermatophytosis: A within person pilot study. Med J Armed Forces India. 2021; 77:117-8.
Bhatia A, Kanish B, Badyal DK, Kate P, Choudhary S. Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin-A prospective, randomized comparative study. Indian J Pharmacol. 2019;51:116-9.
Rudramurthy SM, Shankarnarayan SA, Dogra S, Shaw D, Mushtaq K, Paul RA et al. Mutation in the Squalene Epoxidase Gene of Trichophyton interdigitale and Trichophyton rubrum Associated with Allylamine Resistance. Antimicrob Agents Chemother. 2018;62: e02522-17.
Kumar G, Saxena K, Koti Rao V. A comparative study on efficacy of oral terbinafine and itraconazole on dermatophytic infections. Int J Res Dermatol. 2022;8: 381-7.
Poluri LV, Indugula JP, Kondapaneni SL. Clinicomycological study of dermatophytosis in South India. J Lab Physicians. 2015;7:84-9.
Bishwas S, Kumar S. A comparative study of efficacy of itraconazole versus terbinafine and their cost effectiveness in the treatment of resistant dermatophytosis of skin at Nalanda medical college, a tertiary care teaching hospital of Patna. Global J Res Anal. 2020;9:1-2.
Sharma P, Bhalla M, Thami GP, Chander J. Evaluation of efficacy and safety of oral terbinafine and itraconazole combination therapy in the management of dermatophytosis. J Dermatolog Treat. 2020;31:749-53.
Brigida S, Elizabeth A, Soujania G, Poornima R. A Comparative Study of Safety and Efficacy of Oral Terbinafine and Itraconazole in Patients of Tinea Corporis/ Tinea Cruris Infection, a Randomized Open Label Parallel Group Study. Biomed Pharmacol J. 2021;14:31-5.
